Telix Pharmaceuticals (NASDAQ:TLX) Trading Up 6.6% – Here’s What Happened

Telix Pharmaceuticals Limited (NASDAQ:TLX) shares rose 6.6% on Tuesday . The company traded as high as $8.45 and last traded at $8.39. Approximately 69,684 shares traded hands during mid-day trading, a decline of 71% from the average daily volume of 239,111 shares. The stock had previously closed at $7.87.

Analyst Ratings Changes

TLX has been the subject of several recent analyst reports. Royal Bank Of Canada raised Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday, January 19th. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Telix Pharmaceuticals in a research note on Wednesday, January 21st. Weiss Ratings restated a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Wednesday, January 21st. Citigroup increased their target price on Telix Pharmaceuticals from $22.00 to $22.50 and gave the company a “buy” rating in a report on Tuesday, February 24th. Finally, Wall Street Zen cut Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $21.13.

Telix Pharmaceuticals Stock Up 5.9%

The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. The business has a fifty day simple moving average of $7.32 and a 200-day simple moving average of $8.76.

Telix Pharmaceuticals (NASDAQ:TLX) last issued its quarterly earnings results on Friday, February 20th. The company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.06). On average, equities analysts predict that Telix Pharmaceuticals Limited will post 0.24 earnings per share for the current year.

Institutional Trading of Telix Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in TLX. Millennium Management LLC bought a new stake in Telix Pharmaceuticals in the 3rd quarter valued at $1,883,000. Portland Investment Counsel Inc. boosted its stake in shares of Telix Pharmaceuticals by 108.0% during the 4th quarter. Portland Investment Counsel Inc. now owns 266,200 shares of the company’s stock worth $2,063,000 after purchasing an additional 138,200 shares during the period. Lazard Asset Management LLC grew its holdings in Telix Pharmaceuticals by 118.6% during the 4th quarter. Lazard Asset Management LLC now owns 250,517 shares of the company’s stock valued at $1,876,000 after purchasing an additional 135,893 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in Telix Pharmaceuticals in the 2nd quarter worth about $975,000. Finally, Quadrature Capital Ltd purchased a new stake in Telix Pharmaceuticals in the 4th quarter worth about $276,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.